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1. Introduction 
Cystic fibrosis (CF) is largely a protein misfolding disease. The deletion of a phenylalanine 
at residue 508 (F508) in the cystic fibrosis transmembrane conductance regulator (CFTR) 
accounts for 70% of all disease-causing alleles and is present in at least one copy in 90% of 
CF patients (Kerem et al., 1989). The F508 mutation impairs the conformational maturation 
of nascent CFTR (Lukacs et al., 1994), and arrests it in an early folding intermediate (Zhang 
et al., 1998). As a result, the mutant CFTR is retained in the endoplasmic reticulum (ER) 
(Cheng et al., 1990) in a chaperone-bound state (Yang et al., 1993), The ER-accumulated 
mutant CFTR fails to efficiently couple to the coatomer complex II (COPII) ER export 
machinery (Wang et al., 2004), and is degraded by the ubiquitin proteasome system through 
the ER-associated degradation (ERAD) pathway (Jensen et al., 1995; Ward et al., 1995), 
leading to loss of CFTR function at the cell surface.  
The folding defect of F508 CFTR appears kinetic in nature (Qu et al., 1997). A small 
fraction of F508 CFTR is able to exit the ER but the escaped mutant protein is not stable 
at the cell periphery and is rapidly cleared through lysosomal degradation (Lukacs et al., 
1993). This second defect further reduces the cell surface localization of this mutant 
CFTR. Aside from localization defect, the F508 mutation also impairs the channel gating 
of CFTR, leading to reduced open probability (Dalemans et al., 1991). The threefold 
defect of F508 CFTR stems from its defective conformation, and impairs the CFTR 
functional expression at the cell surface, leading to severe clinical phenotype. Given the 
autosomal recessive inheritance of the disease, improving plasma membrane functional 
expression of F508 CFTR will benefit the vast majority of CF patients (Gelman & 
Kopito, 2002).  
Numerous research efforts have been made to improve F508 CFTR cell surface functional 
expression, including elevating its expression, reducing its degradation, enhancing the 
efficiency of its maturation,  increasing its post-ER stability and improving its channel 
gating. Restoring F508 CFTR conformation will potentially improve its ER folding, its cell 
surface stability and its channel gating, leading to efficient F508 CFTR rescue. In this 
chapter, multiple approaches for F508 CFTR rescue will be reviewed, and their advantages 
as well as limitations will be discussed.  
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2. Overview of CFTR biogenesis, quality control and exocytic trafficking 
CFTR is a member of the ATP-binding cassette (ABC) transporter family, and is composed 
of two homologous modules each containing a membrane spanning domain (MSD) 
followed by a nucleotide-binding domain (NBD) (Riordan et al., 1989) (Fig. 1). CFTR is 
unique in that it has an unstructured regulatory (R) domain inserted between the two 
homologous modules (Fig. 1). CFTR has two N-linked glycosylation sites on the fourth 
extracellular loop (Fig. 1). In the ER, the newly synthesized CFTR acquires core-
glycosylation at these two sites. Upon transport to the Golgi, the core-glycosylation is 
processed into the Golgi-specific complex glycosylation, leading to an up-shift in its 
apparent molecular weight. This difference in processing provides an important means of 
discriminating the ER-localized, immature CFTR (band B) and the Golgi-processed, mature 
form (band C). At the steady state, the majority of CFTR is in its mature form. As F508 
CFTR is unable to exit the ER, it largely exists in band B. All the major functional domains of 
CFTR reside on the cytoplasmic side of membrane. Therefore, chaperone-mediated folding 
events in the cytoplasm play an important role in CFTR maturation and quality control 
(Yang et al., 1993; Loo et al., 1998; Meacham et al., 1999; Wang et al., 2006).  
 
Fig. 1. Domain structure and putative sorting signals of CFTR. 
2.1 CFTR de novo folding in the ER 
CFTR is synthesized on the ER membrane. Domain folding occurs largely co-translationally 
(Kleizen et al., 2005). However, further conformational maturation is necessary to form a 
fully assembled molecule competent for passing the ER quality control and coupling to 
COPII for ER export (Zhang et al., 1998; Wang et al., 2004). The F508 residue resides in 
NBD1 (Fig. 1). The F508-induced misfolding of CFTR starts during translation immediately 
after the NBD1 emerges from the ribosome (Hoelen et al., 2010). This conformational defect 
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originates in NBD1 but spread throughout the whole molecule through domain-domain 
interactions, leading to a global conformation defect (Du et al., 2005; Du & Lukacs, 2009; Roy 
et al., 2010). Restoring wild-type-like global conformation is required for F508 CFTR to 
pass the quality control and egress from the ER (Roy et al., 2010).  Second site mutations in 
NBD1 have been identified that suppress the F508 processing defect (Teem et al., 1993), 
and at least some of such suppressing mutations can act co-translationally on the NBD1 
misfolding (Hoelen et al., 2010). Therefore, the de novo folding of F508 CFTR at both co-
translational and post-translational levels can be targeted for its rescue.  
2.2 CFTR quality control in the ER 
Newly synthesized CFTR undergo quality control before it can exit the ER. ER quality 
control starts even before CFTR is fully translated (Fig. 2). A membrane-associated 
ubiquitin ligase complex containing the E3 RMA1, the E2 Ubc6e and Derlin-1 mediates 
CFTR co-translational quality control (Sun et al., 2006; Younger et al., 2006). BAP31, an 
integral membrane protein that associates with Derlin-1 as well as the amino terminus of 
CFTR, promotes F508 CFTR retrotranslocation from the ER and its subsequent 
degradation by the cytoplasmic 26S proteasome (B. Wang et al., 2008). P97/valosin-
containing protein interacts with gp78/autocrine motility factor receptor in coupling 
CFTR ubiquitination to its retrotranslocation and proteasome degradation (Carlson et al., 
2006; Vij et al., 2006). Interestingly, gp78 was found to cooperate with RMA1 in the ERAD 
of F508 CFTR (Morito et al., 2008). Moreover, ubiquitin C-terminal hydrolase-L1 (UCH-
L1) protects CFTR from co-translational ERAD (Henderson et al., 2010). This co-
translational quality control of CFTR appears to be regulated by cytoplasmic Hsc70 as 
DNAJB12 was recently found to cooperate with Hsc70 and RMA1 in F508 CFTR 
degradation (Grove et al., 2011). Consistent with this, we found that Hsp105, a nucleotide 
exchange factor (NEF) for Hsc70, promotes co-translational ERAD of CFTR (Saxena et al., 
2011a).  
A second ER quality control step occurs largely post-translationally, which is mediated 
through Hsc70 and cochaperone CHIP (Meacham et al., 2001) (Fig. 2). CHIP functions as a 
scaffold for the formation of multi-subunit E3 ubiquitin ligase for the post-translational 
ERAD of CFTR, and such degradation activity is also dependent upon Hsc70, Hdj-2 and the 
E2 UbcH5a (Younger et al., 2004). Interestingly, HspBP1 and BAG-2, two other NEFs for 
Hsc70, inhibits the CHIP-mediated post-translational ERAD of CFTR (Alberti et al., 2004; 
Arndt et al., 2005), suggesting a dual role for Hsc70 in regulating co-translational and post-
translational ERAD of CFTR. 
Nevertheless, inhibiting CFTR ERAD is not sufficient for F508 CFTR to efficiently exit 
the ER (Jensen et al., 1995; Pagant et al., 2007). Obviously, another quality control system 
is responsible for the retention of the foldable pool of F508 CFTR in the ER, the 
mechanism of which is less clear. We recently showed that the ER exit code and domain 
conformation both contribute significantly to the exportability of CFTR (Roy et al., 2010). 
Therefore, chaperone association and/or ER exit code presentation might be two 
important factors for this last checkpoint of the ER quality control of CFTR. A better 
understanding of its mechanism will lead to much greater improvement in F508 CFTR 
maturation. 
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Shown are the transcription, synthesis, folding and quality control of wild-type and F508 CFTR with a 
great number of regulators at both the ER and peripheral levels, which are potential molecular targets 
for F508 CFTR rescue. Complete arrows indicate major pathways, and broken arrows denote minor 
pathways. Enhancement of some of the minor pathways for F508 CFTR can effectively promote its 
rescue.  
Fig. 2. Regulation of CFTR biogenesis and degradation. 
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2.3 ER-to-Golgi sorting signals within CFTR 
Exit of proteins from the ER requires specific sorting signals on the cytoplasmic side of the 
ER membrane which is recognizable by the cargo selection complex (Sec23/24) of COPII 
(Aridor et al., 1998; Nishimura et al., 1999; Miller et al., 2002). A di-acidic ER exit motif 
(DAD) was identified in the NBD1 of CFTR (Fig. 1), and substitution of the second acidic 
residue (leading to DAA) abolishes CFTR association with Sec24 and dramatically reduces 
the export efficiency of CFTR (Wang et al., 2004). The F508 mutation also reduces CFTR 
association with Sec24 (Wang et al., 2004) but the underlying mechanism might be different 
from the DAA mutant. Using in situ limited proteolysis to probe the domain conformation 
of CFTR (Zhang et al., 1998), we showed that the DAA mutant has similar domain 
conformation as wild-type CFTR despite its inability to efficiently exit the ER (Roy et al., 
2010). This is in stark contrast to F508 CFTR which displays global conformational defects 
including NBD1 (Du et al., 2005; Du & Lukacs, 2009; Roy et al., 2010). Furthermore, DAA 
CFTR displays lower chaperone association and higher post-ER stability when compared 
with F508 CFTR (Roy et al., 2010). Therefore, the conformational defects in F508 CFTR 
contribute significantly to its misprocessing. 
ER retention/retrieval signals have been found in the cytoplasmic domains of multiple 
transmembrane cargo proteins (Nilsson et al., 1989; Zerangue et al., 1999).  An RXR ER 
retention/retrieval signal serves as a quality control check point for the assembly of 
oligomeric cargo proteins in the ER (Zerangue et al., 1999; Margeta-Mitrovic et al., 2000). 
The RXR signals are exposed in individual subunits or in incompletely assembled oligomers 
but are concealed only when the proper assembly of the oligomer is achieved. This 
mechanism prevents the cell surface expression of improperly assembled cargo molecules. 
Multiple RXR motifs have been identified in the cytoplasmic domains of CFTR (Fig. 1), and 
the replacement of key arginine residues results in F508 CFTR rescue, suggesting that the 
RXR motifs might contribute to the ER retention/retrieval of F508 CFTR (Chang et al., 
1999). It is proposed that such RXR motifs are shielded by domain-domain interactions in 
wild-type CFTR but become exposed when the F508 is deleted (Kim Chiaw et al., 2009). In 
fact, peptides designed to mimic such a sorting motif were found to functionally rescue 
F508 CFTR (Kim Chiaw et al., 2009). As the key RXR motif in NBD1 contributes 
significantly to F508 CFTR global conformation (Qu et al., 1997; Hegedus et al., 2006; Roy 
et al., 2010), it is unclear if the RXR-mimetics rescue F508 CFTR by influencing F508 CFTR 
conformation. Determining whether the RXR-mimetics are able to bind to the RXR sorting 
receptor or whether they block the retention/retrieval of other RXR-containing cargo 
molecules will provide a definitive answer.  
3. Defining F508 conformational defects 
F508 resides in NBD1 (Fig. 1), and therefore the deletion of this residue should naturally 
affect the conformation of NBD1. Early in vitro studies using purified NBD1 revealed a 
kinetic folding defect in F508 NBD1 (Qu & Thomas, 1996; Qu et al., 1997). However, the 
crystal structure of F508 NBD1 revealed no major conformational change from the wild-
type domain (Lewis et al., 2005). In the mean time, it was found that F508 mutation causes 
major conformation changes in NBD2 (Du et al., 2005), highlighting the importance of 
domain-domain interactions in F508 misfolding. This notion was strengthened by the 
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finding that F508 side chain contributes significantly to NBD1 folding in the context of full-
length CFTR (Thibodeau et al., 2005), and by the finding that F508 residue mediates the 
contact between NBD1 and cytoplasmic loop 4 (CL4) in MSD2 (Serohijos et al., 2008a). 
Therefore, deletion of F508 triggers a global conformational change in CFTR, leading to 
misprocessing (Du & Lukacs, 2009).  
The apparent lack of a detectable NBD1 conformational change as a result of the F508 
mutation remains an enigma as how can the F508 mutation trigger such a profound global 
conformational change without significantly impacting NBD1 conformation in the first 
place? The finding that some of the solubilization mutations included in F508 NBD1 for 
crystallography studies actually rescue the F508 processing defect in the context of full-
length CFTR reopened this question (Pissarra et al., 2008). Another twist in our 
understanding of the impact of F508 deletion on NBD1 conformation came from the finding 
that the removal of the regulatory insert (RI), a 32-residue segment within NBD1 that is 
unique to CFTR but not shared by the NBD1’s of other ABC transporters, renders F508 
NBD1 soluble, dimer-forming and displaying wild-type-like conformation (Atwell et al., 
2010). Another study shows that, in the context of full-length CFTR protein, removal of the 
RI restores maturation, stability and function of F508 CFTR, suggesting that the RI 
contributes significantly to F508 misfolding in NBD1(Aleksandrov et al., 2010).  
Using in situ limited proteolysis, we identified a definite conformational change within 
NBD1 as a result of F508 mutation (Roy et al., 2010). The F508 NBD1 conformation, like 
the conformation of other domains of F508 CFTR, resembles the conformation of an earlier 
folding intermediate of wild-type CFTR (Zhang et al., 1998; Roy et al., 2010). Furthermore, 
rescue of F508 CFTR using low temperature or R555K substitution leads to NBD1 as well 
as global conformational reversion, suggesting that conformational correction is prerequisite 
for the rescue of the folding and export defects of F508 CFTR (Roy et al., 2010). Using 
crystallography and hydrogen/deuterium exchange mass spectrometry, Lewis, et al. 
showed that F508 mutation increases the exposure of the 509-511 loop and increases the 
dynamics in its vicinity (Lewis et al., 2010). Consistent with the above, a conformational 
change in F508 NBD1 was observed using a cysteine-labelling technique, and such 
conformational change is reversed by second site mutations in NBD1 (He et al., 2010). 
Interestingly, the second site mutations also restore the interactions between NBD1 and its 
contacting domains (He et al., 2010). Combination of G550E, R553M and R555K suppressor 
mutations in NBD1 produces a dramatic increase in F508 CFTR processing, and this is 
accompanied by the enhanced folding of F508 NBD1 both in isolation and in the context of 
full-length CFTR (Thibodeau et al., 2010). An interesting finding is that while NBD2 is not 
required for CFTR processing (Pollet et al., 2000), it contributes to F508 CFTR rescue by 
second site mutations as well as by low temperature (Du & Lukacs, 2009; Cheng et al., 2010). 
Furthermore, the rescue of F508 CFTR by suppressor mutations requires a continuous full-
length CFTR peptide (Cheng et al., 2010), suggesting a role for peptide backbone tension in 
F508 CFTR rescue (Thibodeau et al., 2005). 
Taken together, F508 mutation causes increased exposure of the 509-511 loop in NBD1 and 
increases its dynamics. These changes not only alter the conformation of NBD1, but through 
NBD1’s interface with CL4 and NBD2, alter the conformation of other domains, leading to 
global conformational change. Second site mutations within NBD1 can partially correct the 
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F508 NBD1 conformational defect, which spread to other domains through domain-
domain interactions, leading to partial restoration of global conformation as well as 
processing. Conformation repair is at the heart of F508 correction. 
4. Elevating F508 CFTR expression 
The severe reduction in F508 CFTR cell surface functional expression results from its 
defective export, reduced peripheral stability, and subnormal channel gating. Nevertheless, 
a small fraction of the mutant CFTR can leak from the ER and make its way to cell surface. 
One simple approach to enhance F508 CFTR cell surface localization is to increase its 
expression. This can be achieved in cells heterologously expressing F508 CFTR under the 
control of metallothionein promoter by treatment with sodium butyrate (Cheng et al., 1995). 
In CF airway epithelial cells, 4-phenylburyrate, a histone deacetylase (HDAC) inhibitor  
dramatically increases the expression of F508 CFTR at the protein level (Rubenstein et al., 
1997). Recently, a group of other HDAC inhibitors including Trichostatin A, suberoylanilide 
hydroxamic acid (SAHA) and Scriptaid were found to potently increase F508 CFTR 
transcription in CFBE41o- cells (Hutt et al., 2010).  
Interestingly, over-accumulation of F508 CFTR in the ER induces the unfolded protein 
response (UPR) (Gomes-Alves et al., 2010), and induction of UPR inhibits CFTR 
endogenous transcription (Rab et al., 2007). The UPR-induced CFTR transcriptional 
repression is mediated through the transcription factor ATF6, and both DNA methylation 
and histone deacetylation contribute to this process (Bartoszewski et al., 2008). Therefore, 
there is a limit to which the transcription of endogenous F508 CFTR can be increased but 
HDAC inhibitors may potentially alleviate the UPR-induced CFTR transcriptional 
repression (Fig. 2). 
The expression of F508 CFTR can also be regulated at the post-transcriptional level. A 
recent study revealed that the synonymous codon change of I507 in the F508 allele can 
cause mRNA misfolding, leading to reduced rate of translation and/or impaired co-
translational folding of F508 CFTR (Bartoszewski et al., 2010). Therefore, codon-dependent 
mRNA folding represents a new mechanism by which F508 CFTR expression can be 
regulated. Although it is not realistic to change the nucleotide sequence of F508 CFTR in 
CF patients, identification of this novel mechanism opens up new opportunities for 
therapeutic intervention at the level of mRNA processing, folding, and stability. 
5. Reducing F508 CFTR ERAD 
The vast majority of F508 CFTR synthesized in the cells is degraded through the ERAD 
pathway (Jensen et al., 1995; Ward et al., 1995). Inhibition of ERAD will certainly increase 
the steady state level of F508 CFTR in the ER and subsequently increase its cell surface 
localization (Fig. 2). Significant advance in understanding the mechanism of ERAD of F508 
CFTR has been achieved during the past 16 years. Hsc70 has been found to regulate both the 
co-translational and post-translational ERAD of F508 CFTR with two distinct sets of 
cochaperones (Meacham et al., 2001; Zhang et al., 2001; Alberti et al., 2004; Arndt et al., 2005; 
Grove et al., 2011; Saxena et al., 2011a). While the functional relationship between the two 
remains unclear, multiple cochaperones, such as CHIP (Meacham et al., 2001), HspBP1 
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(Alberti et al., 2004), BAG-2 (Arndt et al., 2005), Hdj-2 (Younger et al., 2004), DNAJB12 
(Grove et al., 2011) and Hsp105 (Saxena et al., 2011a) may be targeted for increasing the 
steady state levels of F508 CFTR. Moreover, 4-phenylbutyrate, which rescues F508 CFTR 
(Rubenstein et al., 1997), was found to reduce the expression level of Hsc70, subsequently 
decreases its association with F508 CFTR, and therefore inhibits the ERAD of F508 CFTR 
(Rubenstein & Zeitlin, 2000). More recently, a soluble sulfogalactosyl ceramide mimic that 
inhibits the Hsp40-activated Hsc70 ATPase activity, promotes the rescue of F508 CFTR 
from ERAD (Park et al., 2009). In addition to Hsc70, small heat-shock proteins (sHsps) 
preferentially associate with F508 CFTR and promote its ERAD (Ahner et al., 2007). It is 
believed that small heat-shock proteins bind to misfolded F508 CFTR, prevent its 
aggregation and maintain its solubility during the ERAD (Ahner et al., 2007).   
ERAD components such as RMA1 (Younger et al., 2006), gp78 (Morito et al., 2008), Derlin-1 
(Sun et al., 2006; Younger et al., 2006), BAP31(B. Wang et al., 2008)  and p97 (Carlson et al., 
2006; Vij et al., 2006) can also be targeted. Although not essential for ERAD of CFTR 
(Carlson et al., 2006), interference of p97 expression in CF airway epithelial cells increases 
the steady state levels of F508 CFTR in bands B and C, and enhances the CFTR-mediated 
chloride conductance across the plasma membrane (Vij et al., 2006). Interestingly, this effect 
is accompanied by reduction in interleukin-8 level which might alleviate the CF-associated 
airway inflammation (Vij et al., 2006). Other regulators of the p97-gp78 complex have been 
identified, which also influence the steady state level of F508 CFTR (Nagahama et al., 2009; 
Ballar et al., 2010). Recently, ubiquitin-specific protease 19 (USP19), an ER-localized, 
membrane-anchored deubiquitinating enzyme, was shown to rescue F508 CFTR from 
ERAD (Hassink et al., 2009), suggesting that deubiquitinating enzymes are another class of 
viable targets for rescuing F508 CFTR (Fig. 2).  
6. Enhancing F508 CFTR maturation 
Despite its obvious importance in rescuing F508 CFTR, relatively little is known 
concerning how to improve the maturation of F508 CFTR in the ER. The major reason is 
that F508 CFTR hardly matures if at all at physiological temperature. However, at reduced 
temperature, F508 CFTR does achieve conformational maturation much more efficiently, 
leading to greatly enhanced functional expression at the cell surface (Denning et al., 1992). 
Interestingly, such a temperature-sensitive phenotype is cell-dependent, suggesting that 
cellular machinery plays an essential role in the process (X. Wang et al., 2008). We found 
that the increased conformational stability provided by low temperature combines with 
chaperone actions in facilitating F508 CFTR maturation at reduced temperature (Roy et al., 
2010). Therefore, the temperature-dependent maturation of F508 CFTR serves as an 
excellent model system in understanding the role of the cellular chaperone machinery in the 
forward folding of F508 CFTR.  
Mild heat shock greatly potentiates the temperature rescue of F508 CFTR, and this is 
dependent upon transcription, suggesting that the upregulation of heat inducible 
chaperones promotes F508 CFTR maturation (X. Wang et al., 2008). Using a series of 
chaperone- or cochaperone-deficient cell lines, we demonstrate that an Hsp70-Hsp90 
chaperone network operates on the cytoplasmic face of the ER membrane facilitating the 
maturation of F508 CFTR at reduced temperature. Cochaperone Hop, which physically 
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and functionally links Hsp70 and Hsp90 through its multiple tetratricopeptide repeat (TPR) 
domains, is essential for the temperature-dependent maturation of F508 CFTR, and  
Hsp105 is an integral player in the system (Saxena et al., 2011b). We also found that Hsc70, 
Hsp90, Hop, Hsp105 and Hdj-2 are functionally linked during the temperature rescue of 
F508 CFTR. Depletion of Hsp90, Hop or Hsp105 also reciprocally reduces some or all of 
other chaperone components (Saxena et al., 2011b). It is highly likely that these folding 
components, and perhaps other yet unidentified chaperones or cochaperones, form a 
functionally organized chaperone network on the cytoplasmic side of the ER membrane, 
facilitating the conformational maturation of F508 CFTR at reduced temperature. Given a 
clear role for Hsp90 in wild-type CFTR maturation at physiological temperature (Loo et al., 
1998), we believe such a cytoplasmic chaperone network functions in the cell under 
physiological conditions. While its effect on F508 CFTR maturation is more pronounced at 
reduced temperature, it should also impact F508 CFTR maturation at the physiological 
temperature.  Consistent with this prediction, overexpressing Hsp105 promotes F508 CFTR 
processing at both the reduced and physiological temperatures (Saxena et al., 2011a). An in-
depth analysis of this process will reveal novel molecular targets that promote the 
maturation of F508 CFTR (Fig. 2).  
Another approach to enhance F508 CFTR maturation is through transcomplementation 
(Cormet-Boyaka et al., 2004). Such rescue requires co-expression of a sizeable segment of 
CFTR that contains wild-type sequence corresponding to the region where F508 is located. 
Such transcomplementation does not result in changes in Hsc70 association but is believed 
to improve F508 CFTR forward folding through intra- and/or inter-molecular domain-
domain interactions. A related but distinct approach to promote F508 CFTR maturation is 
to co-express a fragment of F508 CFTR containing NBD1 and R domains (Sun et al., 2008). 
This mutant fragment of CFTR can actually sequester key chaperone components from the 
endogenous F508 CFTR and lead to its rescue. Moreover, co-expressing an N-terminal 
truncated CFTR mutant (264) can not only transcomplement F508 CFTR but also 
dramatically increases the protein expression levels of both wild-type and F508 CFTR 
(Cebotaru et al., 2008). As the 264 mutant CFTR associates with VCP and HDAC6, two 
components involved in retrotranslocation of proteins from the ER, and is more efficiently 
degraded by the proteasome than F508 CFTR, high level expression of this mutant may 
interfere with F508 CFTR ERAD and hence increase its steady state level. Taken together, 
co-expression of CFTR fragments might rescue F508 CFTR by improving its folding, 
helping it escape ER quality control and protecting it from ERAD. As these fragments have 
much lower molecular weight than full-length CFTR, they can be used as potential agents 
for CF gene therapy. 
7. Increasing F508 CFTR peripheral stability 
The F508 CFTR has reduced conformational stability in post-ER compartments and 
therefore turns over rapidly at the cell periphery (Lukacs et al., 1993; Sharma et al., 2001; 
Sharma et al., 2004). Increasing F508 CFTR half-life at cell periphery is an important 
strategy for effective rescue of F508 CFTR. CAL, a Golgi-associated, PDZ domain-
containing protein that binds to the C-terminus of CFTR, reduces the half-life of CFTR at the 
cell surface (Cheng et al., 2002). RNA interference of endogenous CAL in CF airway 
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epithelial cells increases plasma membrane expression of F508 CFTR and enhances 
transepithelial chloride current (Wolde et al., 2007). The Na+/H+ exchanger regulatory factor 
(NHERF), a subplasma membrane PDZ domain protein, competes with CAL in associating 
with CFTR and promotes its plasma membrane localization (Cheng et al., 2002). Knockdown 
of NHERF1 promotes the degradation of temperature-rescued F508 CFTR at the cell 
surface of human airway epithelial cells (Kwon et al., 2007). Expression of dominant-
negative dynamin 2 mutant K44A increases CFTR cell surface expression, and counteracts 
the effect of CAL overexpression on CFTR cell surface stability (Cheng et al., 2004).  SNARE 
protein syntaxin 6 binds to CAL and reduces CFTR cell surface stability in a CAL-dependent 
manner (Cheng et al., 2010). Therefore, CAL and its functional partners are viable molecular 
targets for increasing cell surface stability of F508 CFTR (Fig. 2). 
Cytoplasmic chaperone Hsc70 was shown to mediate the uncoating of clathrin-coated 
vesicles (Schmid & Rothman, 1985; Chappell et al., 1986) and hence regulates the peripheral 
trafficking of membrane bound cargo proteins such as CFTR. Recently, a more direct role for 
cytoplasmic Hsp70-Hsp90 chaperone network in regulating F508 CFTR peripheral quality 
control was revealed, where Hsc70, Hsp90, Hop and other chaperone components  
collaborate with the ubiquitin system in promoting the cell surface degradation of this 
mutant CFTR (Okiyoneda et al., 2010). This finding uncovers a great number of new 
potential chaperone targets for regulating cell surface stability of F508 CFTR. However, as 
the cytoplasmic Hsp70-Hsp90 chaperone network also facilitates the maturation of CFTR in 
the ER (Loo et al., 1998; Meacham et al., 1999; Wang et al., 2006), a critical balance must be 
maintained between the two seemingly opposing effects of the Hsp70-Hsp90 chaperone 
network at the ER and the peripheral levels in order to effectively rescue F508 CFTR  
(Fig. 2).  
Of particular interest, we found that Hsp105 is involved in both processes. At the ER level, 
Hsp105 facilitates the Hsp70-Hsp90-mediated maturation of F508 CFTR at reduced 
temperature (Saxena et al., 2011b). At the peripheral level, Hsp105 preferentially associates 
with the rescued F508 CFTR, and stabilizes it in post-ER compartments (Saxena et al., 
2011a). It is currently unclear whether Hsp105 functionally relates to Hsc70, Hop and 
Hsp90 at the cell periphery or it act on its own. While Hsp105 acts in the same direction as 
the cytoplasmic Hsp70-Hsp90 network at the ER level, it acts in opposite direction to Hsc70, 
Hop and Hsp90 at the cell periphery. Understanding these aspects is critical to the effective 
enhancement of F508 CFTR cell surface functional expression by modulating cytoplasmic 
chaperone machinery. 
8. Improving F508 CFTR channel gating: Potentiator or corrector? 
Although the primary defect in F508 CFTR is impaired export (Cheng et al., 1990), it has 
aberrant channel gating as reflected in reduced channel open probability (Dalemans et al., 
1991). Correcting such a defect will also improve the overall cell surface functional expression 
of F508 CFTR. The G551D substitution in CFTR, a mutation causing severe CF,  does not 
impact its export to plasma membrane but primarily impairs its channel opening (Tsui, 1995; 
Li et al., 1996). VX-770, a small molecule potentiator (improving channel gating) developed for 
G551D CFTR by the Vertex Pharmaceuticals Inc., also increases the channel open probability 
of F508 CFTR (Van Goor et al., 2009). Interestingly, small molecule compound VRT-532 
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display both corrector (improving maturation) and potentiator activities for F508 CFTR by 
binding directly to the mutant protein (Wellhauser et al., 2009). Recently, a fragment of a 
phenylglycine-type potentiator was successfully linked to a fragment of a bithiazole corrector 
to form a “hybrid” potentiator-corrector molecule, the cleavage of which by intestinal enzymes 
is able to release separate potentiator and corrector for F508 rescue in vivo (Mills et al., 2010). 
Using high-throughput screen, multiple small molecules with independent potentiator and 
corrector activities for F508 CFTR were also identified (Phuan et al., 2011). Using the above 
approaches, more efficient rescue of F508 CFTR can be achieved.  
9. Conformational repair: One stone and three birds 
Given that the root cause of CF in the majority of patients lies in the conformational defects 
of F508 CFTR, repairing its conformational defects will potentially lead to improved 
export, stability (both in the ER and at the cell periphery) and channel gating. Effective 
development of novel approaches in conformational repair relies on a thorough 
understanding of the conformational defects of F508 CFTR and their correction. Given that 
F508 residue resides in NBD1, NBD1 is a central domain for the understanding of F508 
conformational repair. In addition, as domain-domain interactions within CFTR play an 
important role in altering or maintaining CFTR global conformation (Du et al., 2005; Du & 
Lukacs, 2009), key interfaces between different domains are also important in CFTR 
conformational repair (Serohijos et al., 2008a).  
An excellent attempt was made early on in screening for suppressor mutations in NBD1 
which restores the export of F508 CFTR (Teem et al., 1993). This was made possible by 
swapping a portion of CFTR NBD1 into yeast STE6 gene encoding an ABC transporter that 
delivers -factor out of the cell which is necessary for mating. When F508 mutation is 
included into the STE6-CFTR chimera, the yeast fails to transport -factor. Using this 
system, second site mutations within the CFTR NBD1 portion were identified that rescue 
F508 CFTR (Teem et al., 1993; Teem et al., 1996). Interestingly, R555K, one of such F508 
suppressor mutations, causes a global conformational reversion in F508 CFTR, leading to 
increased export and enhanced post-ER stability (Roy et al., 2010). R555K, when combined 
with other rescue subsitutions, improves F508 CFTR conformation and processing (Chang 
et al., 1999; Hegedus et al., 2006), and significantly increases the open probability of F508 
CFTR (Roxo-Rosa et al., 2006). These data support the notion that conformational repair is a 
highly effective approach for enhancing F508 CFTR cell surface functional expression, 
ameliorating all three facets of F508 defect.  
Another approach for designing NBD1 conformational repair employs molecular dynamics 
simulation. Molecular dynamics has the advantage over structural biology in that it reveals 
information on folding kinetics and dynamics. Using this approach, key differences in the 
distribution of meta-stable intermediates have been identified between wild-type and F508 
NBD1, and additional rescue mutations can be designed (Serohijos et al., 2008b). These 
rescue mutations, if validated experimentally, will significantly advance our understanding 
of NBD1 folding both alone and in the context of full-length CFTR. 
High resolution crystal structure of full-length CFTR is currently unavailable. However, the 
crystal structures of multiple ABC transporters including the p-glycoprotein have been 
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solved (Locher et al., 2002; Dawson & Locher, 2006; Aller et al., 2009). Attempts to use these 
structures as bases for modeling full-length CFTR have provided new insights into the role 
of F508 residue in domain-domain interactions (Jordan et al., 2008; Loo et al., 2008; Serohijos 
et al., 2008a; Mornon et al., 2009). These studies, when backed up by biochemical analyses, 
are an excellent start point to probe F508 global conformational defects and their repair. 
10. Large-scale target identification for the rescue of F508 CFTR 
Aside from the above mechanism-based identification of therapeutic targets for F508 
rescue, several large-scale target identification regimes have been quite successful. The 
functional follow-up of these studies has yielded and will yield many novel molecular 
targets. 
The first such attempt was to use proteomics to identify CFTR-interacting proteins between 
wild-type and F508 CFTR (Wang et al., 2006), which revealed, among others, an ER-
associated chaperone network facilitating CFTR biogenesis and quality control. In an 
attempt to gain information on the potential mechanism of F508 chemical rescue by 4-
phenylbutyrate, a pharmacoproteomic approach was used to identify changes in protein 
expression in CF airway epithelial cells in response to 4-phenylbutyrate treatment (Singh et 
al., 2006). This approach was then followed by a comparison of F508 CFTR-interacting 
proteins between the chemically rescued (by 4-phenylbutyrate) and genetically repaired (by 
introducing wild-type CFTR) CF airway epithelial cells (Singh et al., 2008). Protein targets 
involved in the ERAD, protein folding and inflammatory response have been identified, and 
proteins that were modulated in the ER as well as on the plasma membrane have been 
isolated (Singh et al., 2008).  
Recently, a high-throughput functional screen was designed to identify proteins that 
promote the rescue of F508 CFTR (Trzcinska-Daneluti et al., 2009). In this study, 450 
different proteins were fused to a chloride-senstive yellow fluorescent protein and were 
expressed in a F508 CFTR-expressing stable cell line. The cells were screened for their 
ability to rescue the F508 functional defect at the plasma membrane. Several proteins that 
are known to rescue F508 CFTR as well as novel target proteins have been identified. 
Further functional characterization will reveal their usefulness as potential therapeutic 
targets. 
Another excellent approach worth noting is the use of functional small interfering RNA 
screen to identify proteins that are involved in peripheral quality control of F508 CFTR 
(Okiyoneda et al., 2010). This approach took advantage of a well developed cell surface 
ELISA assay measuring CFTR plasma membrane localization, where three HA-tags have 
been engineered in an extracellular domain of CFTR. The siRNAs targeting a great number 
of ubiquitin E3 ligases, ESCRT proteins, E2 enzymes and chaperone/cochaperones were 
introduced into the above cells, and the plasma membrane stability of the rescued F508 
CFTR-3HA was quantified. This study led to the identification of an Hsp70-Hsp90 
chaperone network facilitating the peripheral quality control of F508 CFTR. Functional 
followup of these chaperone proteins will not only reveal critical mechanistic information 
but also uncover yet unidentified molecular targets. 
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11. Small molecule modulators for F508 CFTR  
One of the major strategies for developing effective therapeutics for CF is to identify small 
molecule compounds that can improve F508 CFTR cell surface functional expression. 
Using cell-based functional assay for CFTR-mediated chloride conductance combined with 
high-throughput screening of small molecule compound libraries, multiple CFTR 
modulators have been identified, affecting F508 CFTR trafficking and/or channel function 
(Van Goor et al., 2006; Verkman et al., 2006). Once promising scafolds have been identified, 
structural optimization can be performed to enhance their biological activities, 
pharmacokinetics, and safety. In fact several of the above compounds are currently in 
clinical trial for treating CF. 
While the functional screening as mentioned above has the benefit of identifying small 
molecule compounds that improve the aggregate endpoint readout on F508 CFTR cell 
surface functional expression, the mechanisms by which these compounds do so are 
unknown. The compounds can either bind directly to CFTR to affect its folding and/or 
channel gating, or they can bind to other cellular proteins that regulate CFTR biogenesis, cell 
surface protein-protein interactions, or its degradation. Understanding these mechanistic 
aspects of a specific CFTR modulator will lead to the design and identification of additional 
molecular targets and CFTR modulators. This is especially important as only a limited 
number of efficacious CFTR modulators have been identified through the functional screen. 
In order to obtain an FDA-approved drug for CF, more of such compounds are desparately 
needed to feed into the CF drug discovery pipeline.  
Recently, new screening strategies have been designed to improve the variety of workable 
lead compounds. These compounds might not have been identified during the functional 
screen because they do not provide the above-the-threshold functional readouts. However, 
if they have special properties that can enhance certain key aspects of F508 CFTR rescue, 
such compounds can be further engineered or optimized to produce a much greater efficacy 
in terms of functional rescue of F508 CFTR. A new strategry has been developed where 
small molecule compound libraries were screened by their ability to improve the plasma 
membrane localization of F508 CFTR (Carlile et al., 2007).  
A conformation-based virtual screen for F508 CFTR modulators represents one step further 
as it aims at the core defect of F508 CFTR (i.e. abberrant conformation). Recently, one 
attempt was made by the EPIX Pharmaceuticals Ltd to identify small molecule correctors for 
F508 CFTR (Kalid et al., 2010). In this study, a total of three potential small molecule 
binding cavities were identified at a number of domain-domain interfaces of CFTR, and 
small molecule compounds were screened in silico for their ability to bind to these cavities. 
The initial hits derived from the virtual screen were then subjected to functional screen, 
which yielded a ten-fold increase in hit rate as compared to conventional screen regimes.  
An alternative to the above high-throughput screening approach is to explore the possibility of 
using FDA-approved drugs for other conditions or other small molecule compounds that are 
safe for human use for rescuing F508 CFTR. Sodium 4-phenylbutyrate is approved for clinical 
use in patients with urea cycle disorders. 4-Phenylbutyrate, like sodium butyrate, is also a 
transcriptional regulator that inhibits HDAC (Jung, 2001). 4-Phenylbutyrate was shown to 
rescue F508 CFTR through a number of mechanisms including biosynthesis, folding and 
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transport (Rubenstein et al., 1997; Rubenstein & Zeitlin, 2000; Choo-Kang & Zeitlin, 2001; 
Wright et al., 2004; Singh et al., 2006). More recently, SAHA (Vorinostat), an HDAC inhibitor 
approved by FDA for the treatment of cutaneous T cell lymphoma through epigenetic 
pathways (Monneret, 2007), was shown to restore cell surface functional expression of F508 
CFTR to 28% of wild-type level (Hutt et al., 2010). Doxorubicin (Adriamycin), a cancer 
chemotherapy agent, increases cell surface functional expression of F508 CFTR through 
increasing its folding, promoting its chaperone dissociation and inhibiting its ubiquitination 
(Maitra et al., 2001; Maitra & Hamilton, 2007). Sildenafil (Viagra) was also shown to promote 
F508 CFTR apical trafficking by unknown mechanism (Dormer et al., 2005). S-
Nitrosoglutathione (GSNO), an endogenous bronchodilator (Gaston et al., 1993), was found to 
increase the expression and maturation of F508 CFTR in airway epithelial cells (Zaman et al., 
2006). Interestingly, GSNO was recently found to function at least in part through inhibiting 
Hop expression (Marozkina et al., 2010), suggesting that small molecules compound can 
promote F508 CFTR rescue through modulating chaperone machinery. 
12. Chaperone environment: A critical but complex part of the equation  
Cellular chaperone machinery plays an important role in the synthesis, maturation, quality 
control of CFTR (Fig. 2). Due to misfolding, F508 CFTR has more extensive association 
with molecular chaperones (Yang et al., 1993; Jiang et al., 1998; Meacham et al., 1999; Wang 
et al., 2006; Sun et al., 2008; Roy et al., 2010). Therefore, the impact of chaperone machinery 
on F508 CFTR is greater than on wild-type CFTR. This notion is further underscored by the 
recent finding that cytoplasmic Hsp70-Hsp90 chaperone network promotes the peripheral 
quality control of F508 CFTR (Okiyoneda et al., 2010). Modulating chaperone environment 
can not only impact the quality control of F508 CFTR at either the ER or the peripheral 
level but also can dramatically influence its maturation (Loo et al., 1998; Zhang et al., 2002; 
Saxena et al., 2007; Saxena et al., 2011b).  
Heat shock response is a transcriptional program by which cells upregulate the expression 
of an array of genes including those encoding molecular chaperones to cope with the 
massive need for protein folding and degradation as a result of elevated temperature or 
toxic agents (Morimoto et al., 1990). Therefore, conditions or agents that induce heat shock 
response will up-regulate the cellular chaperone machinery to enhance folding and ERAD of 
F508 CFTR. Consistent with this finding, mild heat shock dramatically potentiates the 
temperature-rescue of F508 CFTR (X. Wang et al., 2008). Another cellular response that up-
regulate the cellular chaperone machinery is the unfolded protein response (UPR) (Sidrauski 
et al., 1998). This is particularly relevant to F508 CFTR as over accumulation of this mutant 
protein in the ER induces such a response, leading to downregulation of CFTR endogenous 
transcription (Rab et al., 2007; Bartoszewski et al., 2008). Aside from the above two, the 
inherent variation in the cellular chaperone machinery among different tissues or cell types 
will also significantly affect the cell surface functional expression of F508 CFTR (Varga et 
al., 2004; X. Wang et al., 2008; Rowe et al., 2010). Therefore, understanding the functional 
organization of the chaperone machinery in airway epithelial cells is highly relevant to the 
development of effective rescue strategies for F508 CFTR. 
Certain chemicals such as celastrol can globally influence the cellular chaperone machinery 
through inducing the heat shock response (Westerheide et al., 2004). Other epigentic 
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modulators can also influence the expression of mutliple molecular chaperones (Wright et 
al., 2004; Hutt et al., 2010). Interfering with ER lumenal chaperone activities by depleting the 
ER calcium stores promotes the escape of F508 CFTR from the ER quality control and 
enhances its cell surface expression (Egan et al., 2002). Certain small molecule compounds 
directly modulate the expression or activity of molecular chaperones (Jiang et al., 1998; Loo 
et al., 1998; Marozkina et al., 2010). Furthermore, small molecule compound can act as 
chemical chaperones to stabilize the conformation of F508 CFTR, enhancing its cell surface 
functional expression (Brown et al., 1996; Fischer et al., 2001).  
13. Conclusion 
The F508 mutation is present in over 90% of CF patients. This mutation impairs the 
conformational maturation of CFTR leading to defective export, reduced stability and 
abberrant channel gating. Improving the cell surface functional expression of this mutant 
CFTR will benefit the vast majority of CF patients. While many approaches can be taken 
toward this goal, conformational rescue is the most effective, postitively impacting all 
three molecular defects of F508 CFTR. The F508 CFTR molecule is the most important 
target for the development of therapeutics. A clear understanding of its biogenesis, 
quality control and conformation is fundamental. In the cell, the synthesis, folding, 
quality control, trafficking and degradation of CFTR is dependent upon its interactions 
with multiple cellular machineries (Fig. 2). Such interactions provide additional 
opportunites for therapeutic interventions. The cellular protein homeostasis as regulated 
by the chapeorone machinery provides an important chemical environment for F508 
CFTR. Such an enironment is regulated by multiple cellular responses or epigenetic 
modulators. Understanding the relationship between such cellular environment and 
F508 CFTR cell surface functional expression will provide additional molecular targets 
for intervention.  
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